IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 1, 2015, Pages 18-27

  Shen, Jiayun ^a   Shang, Qing ^a   Wong, Chun Kwok ^a   Li, Edmund K ^a   Wang, Shang ^a   Li, Rui Jie ^a   Lee, Ka Lai ^b   Leung, Ying Ying ^c   Ying, King Yee ^d   Yim, Cheuk Wan ^e   Kun, Emily W ^f   Leung, Moon Ho ^g   Li, Martin ^a   Li, Tena K ^a   Zhu, Tracy Y ^a   Yu, Shui Lian ^a   Kuan, Woon Pang ^a   Yu, Cheuk Man ^a   Tam, Lai Shan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e TSEUNG KWAN O HOSPITAL   (Hong Kong)

^f Taipo Hospital   (Hong Kong)

^g QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Atherosclerosis; Carotid plaque; Disease remission; Early rheumatoid arthritis; IL 33; Soluble ST2

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SOLUBLE ST2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ATHEROSCLEROSIS; DAS28; DISEASE ACTIVITY; EARLY RHEUMATOID ARTHRITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT RESPONSE; WAIST HIP RATIO; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CAROTID ARTERY DISEASES; COMPLICATION; DISEASE COURSE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-33; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84937736650     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.02.001     Document Type: Article

References (50)

1. Harris E.D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289.
2. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
3. Ma M.H., Scott I.C., Kingsley G.H., Scott D.L. Remission in early rheumatoid arthritis. J Rheumatol 2010, 37:1444-1453.
4. Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011, 70:4-7.
5. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
6. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697.
7. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
8. Kremers H.M., Crowson C.S., Therneau T.M., Roger V.L., Gabriel S.E. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008, 58:2268-2274.
9. Young A., Koduri G., Batley M., Kulinskaya E., Gough A., Norton S., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46:350-357.
10. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
11. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121:S21-S31.
12. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., Pineiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
13. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A., Garcia-Porrua C., Testa A., Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1219-1223.
14. Giles J.T., Post W.S., Blumenthal R.S., Polak J., Petri M., Gelber A.C., et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011, 63:3216-3225.
15. Zampeli E., Protogerou A., Stamatelopoulos K., Fragiadaki K., Katsiari C.G., Kyrkou K., et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012, 14:R44.
16. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
17. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
18. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7:321-329.
19. Li H., Tago K., Io K., Kuroiwa K., Arai T., Iwahana H., et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics 2000, 67:284-290.
20. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008, 105:10913-10918.
21. Palmer G., Talabot-Ayer D., Lamacchia C., Toy D., Seemayer C.A., Viatte S., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60:738-749.
22. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37:18-25.
23. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013.
24. Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D.L., Gabay C., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012, 79:32-37.
25. Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139.
26. Matsuyama Y., Okazaki H., Hoshino M., Onishi S., Kamata Y., Nagatani K., et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int 2012, 32:1397-1401.
27. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
28. Tam L.S., Shang Q., Li E.K., Wong S., Li R.J., Lee K.L., et al. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis-a prospective study. Semin Arthritis Rheum 2013, 42:333-345.
29. Tam L.S., Shang Q., Li E.K., Wang S., Li R.J., Lee K.L., et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis-a randomized trial. J Rheumatol 2012, 39:2267-2275.
30. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
31. Aletaha D., Ward M.M., Machold K.P., Nell V.P., Stamm T., Smolen J.S. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005, 52:2625-2636.
32. Felson D.T., Smolen J.S., Wells G., Zhang B., van Tuyl L.H., Funovits J., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586.
33. Orces C.H., Del Rincon I., Abel M.P., Escalante A. The number of deformed joints as a surrogate measure of damage in rheumatoid arthritis. Arthritis Rheum 2002, 47:67-72.
34. Pincus T., Swearingen C., Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999, 42:2220-2230.
35. Yu C.M., Zhang Q., Lam L., Lin H., Kong S.L., Chan W., et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007, 93:933-939.
36. Tam L.S., Shang Q., Li E.K., Tomlinson B., Chu T.T., Li M., et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59:1322-1331.
37. Xu D., Jiang H.R., Li Y., Pushparaj P.N., Kurowska-Stolarska M., Leung B.P., et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010, 184:2620-2626.
38. Verri W.A., Souto F.O., Vieira S.M., Almeida S.C., Fukada S.Y., Xu D., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010, 69:1697-1703.
39. McLaren J.E., Michael D.R., Salter R.C., Ashlin T.G., Calder C.J., Miller A.M., et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010, 185:1222-1229.
40. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
41. Aoki S., Hayakawa M., Ozaki H., Takezako N., Obata H., Ibaraki N., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010, 335:75-81.
42. Demyanets S., Konya V., Kastl S.P., Kaun C., Rauscher S., Niessner A., et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011, 31:2080-2089.
43. Tu X., Nie S., Liao Y., Zhang H., Fan Q., Xu C., et al. The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population. Am J Hum Genet 2013, 93:652-660.
44. Januzzi J.L. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 2013, 6:493-500.
45. Diaz-Jimenez D., Nunez L.E., Beltran C.J., Candia E., Suazo C., Alvarez-Lobos M., et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011, 17:2181-2190.
46. Oshikawa K., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., Ohno S., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001, 164:277-281.
47. Brunner M., Krenn C., Roth G., Moser B., Dworschak M., Jensen-Jarolim E., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004, 30:1468-1473.
48. Tang S., Huang H., Hu F., Zhou W., Guo J., Jiang H., et al. Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis. Clin Dev Immunol 2013, 2013:985301.
49. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104:282-287.
50. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.